Nymox Pharmaceutical Corporation
| NASDAQ: NYMX | Healthcare / Biotechnology / Canada |
| 2.53 | -0.0100 | -0.39% | Vol 122.53K | 1Y Perf -17.26% |
| Jan 15th, 2021 16:00 DELAYED |
| BID | 2.41 | ASK | 2.75 | ||
| Open | 2.60 | Previous Close | 2.54 | ||
| Pre-Market | - | After-Market | - | ||
| - -% | - - |
| Target Price | - | Analyst Rating | — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★ 47.44 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 195.34M | Earnings Rating | Neutral | |
| Price Range Ratio 52W % | 27.80 | Earnings Date | 11th Nov 2020 |
Today's Price Range 2.502.60 | 52W Range 1.664.79 | 5 Year PE Ratio Range -9.50-12.30 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Neutral |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.93% | ||
| 1 Month | 15.98% | ||
| 3 Months | 8.09% | ||
| 6 Months | -26.38% | ||
| 1 Year | -17.26% | ||
| 3 Years | -25.07% | ||
| 5 Years | 15.45% | ||
| 10 Years | -69.91% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2 659.20 | |||
ROE last 12 Months | -249.91 | |||
ROA (5Y Avg) | -208.05 | |||
ROA last 12 Months | -180.11 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -253.02 | |||
Return on invested Capital Q | -273.62 | |||
Return on invested Capital Y | -248.71 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -15.00 | ||||
| 54.23 | ||||
| 41.39K | ||||
| 76.80 | ||||
| -25.00 | ||||
| -0.14 | ||||
| 54.23 | ||||
| 0.05 | ||||
| 203.20M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.80 | ||||
| 3.00 | ||||
| 0.08 | ||||
| 0.02 | ||||
| -2 065.30 | ||||
| Leverage Ratio | 2.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 64.50 | ||||
| -39 454.80 | ||||
| -38 506.50 | ||||
| -7 370.70 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 5.00K | ||||
| 0.00 | ||||
| -61.99 | ||||
| -59.38 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2020 | - | -0.06 | - |
| Q02 2020 | - | -0.04 | - |
| Q01 2020 | - | -0.04 | - |
| Q04 2019 | - | -0.04 | - |
| Q03 2019 | - | -0.04 | - |
| Q02 2019 | - | -0.08 | - |
| Q01 2019 | - | -0.04 | - |
| Q03 2018 | - | -0.05 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 122.53K |
| Shares Outstanding | 77.21M |
| Trades Count | 157 |
| Dollar Volume | 417.88K |
| Avg. Volume | 119.26K |
| Avg. Weekly Volume | 99.19K |
| Avg. Monthly Volume | 163.14K |
| Avg. Quarterly Volume | 148.41K |
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) stock closed at 2.54 per share at the end of the most recent trading day (a -0.78% change compared to the prior day closing price) with a volume of 134.66K shares and market capitalization of 195.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 5 people. Nymox Pharmaceutical Corporation CEO is Paul Averback.
The one-year performance of Nymox Pharmaceutical Corporation stock is -17.26%, while year-to-date (YTD) performance is 2.42%. NYMX stock has a five-year performance of 15.45%. Its 52-week range is between 1.66 and 4.79, which gives NYMX stock a 52-week price range ratio of 27.80%
Nymox Pharmaceutical Corporation currently has a PE ratio of -15.00, a price-to-book (PB) ratio of 54.23, a price-to-sale (PS) ratio of 41 385.20, a price to cashflow ratio of 76.80, a PEG ratio of 2.32, a ROA of -180.11%, a ROC of -253.02% and a ROE of -249.91%. The company’s profit margin is -%, its EBITDA margin is -38 506.50%, and its revenue ttm is $5.00 Thousand , which makes it $0.00 revenue per share.
Of the last four earnings reports from Nymox Pharmaceutical Corporation, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Nymox Pharmaceutical Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Nymox Pharmaceutical Corporation is — (0), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Nymox Pharmaceutical Corporation stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Nymox Pharmaceutical Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Nymox Pharmaceutical Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.67, ATR14 : 0.37, CCI20 : 27.53, Chaikin Money Flow : 73.44, MACD : 0.09, Money Flow Index : 60.96, ROC : 0.40, RSI : 49.94, STOCH (14,3) : 89.34, STOCH RSI : 0.00, UO : 76.60, Williams %R : -10.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Nymox Pharmaceutical Corporation in the last 12-months were:
Nymox Pharmaceutical Corporation
Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and its subsidiaries specialize in research and development of drugs and diagnostic products for the aging population. Its product portfolio consists of Nic alert and Tobac alert. The firm has Research and development of products for the aging population reportable segment. It operates mainly in Canada, the United States and Europe and other countries. The company generates a majority of its sales from the United States.
CEO: Paul Averback
Teplephone: +1 800 936-9669
Address: Bay & Deveaux Streets, Nassau , , BHS
Number of employees: 5
